| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |
| These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study. Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore.. |